Integrum AB

Integrum AB has a current ratio of 4.54, indicating strong short-term liquidity, and a debt-to-equity ratio of 0.03, suggesting a conservative capital structure with minimal leverage. The company's total equity of 177,660,910 SEK supports its total assets of 203,062,960 SEK, while its total liabilities of 25,402,050 SEK are relatively low. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. The company's profitability metrics are concerning, with a return on equity of -17.35% and a return on assets of -15.18%. These figures indicate that Integrum AB is not generating returns for its shareholders or effectively utilizing its assets. The operating income of -42,126,080 SEK and net income of -30,816,930 SEK further underscore the company's financial challenges. The gross profit of 75,381,990 SEK is a positive sign, but it is insufficient to offset the company's operating expenses. Integrum AB's revenue is concentrated in a single business segment focused on bone-anchored prostheses. The company does not disclose geographic revenue breakdowns, but its operations are primarily based in Sweden. This lack of geographic diversification could expose the company to regional economic or regulatory risks. The company's growth trajectory is mixed. Analysts estimate a revenue increase to 110,900,000 SEK in the next fiscal year, representing a growth of approximately 21.7% from the current year's revenue of 91,100,000 SEK. However, the company's operating cash flow of -38,320,150 SEK and free cash flow of -36,158,690 SEK indicate ongoing cash flow challenges. The capital expenditure of -11,887,460 SEK suggests the company is investing in its operations, but the negative cash flows may limit its ability to sustain these investments. The risk assessment for Integrum AB highlights medium liquidity risk and low dilution risk. The company's negative net cash position is a key liquidity concern, and while the dilution risk is low, the company's financial performance may necessitate future equity raises. The risk assessment does not indicate any significant regulatory or geopolitical risks, but the company's reliance on a single product line and geographic concentration could pose operational risks. Recent financial filings and analyst estimates indicate that Integrum AB is facing financial challenges. The company's mean price target of 32.58 SEK is consistent across all estimates, but the mean EPS estimate of -1.97 SEK suggests continued losses. The company's last actual EPS of -1.43 SEK and revenue of 91,100,000 SEK indicate that the company is not meeting analyst expectations. The company's financial performance and cash flow issues are likely to be key topics in upcoming investor communications.